Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility

• Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure.
• With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership position in the life sciences.
• This project will create 12 new jobs and protect 183 existing positions, unlocking new market opportunities and strengthening the sector's competitiveness.

MUMBAI, India, Sept. 30, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), today announced that its Aurora, Canada drug substance site has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialize Ontario-made health technologies for new markets.

With support from the government of Ontario, Piramal Pharma is investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering domestic production of APIs. This project will enhance R&D and clinical API production, ensure the commercial availability of critical drug substances, and support a resilient and globally competitive life sciences industry in Ontario. The investment will create 12 new jobs and protect 183 existing positions.

"We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility," said Peter DeYoung, CEO, Piramal Global Pharma. "This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world. In addition to supporting business growth, this investment will help advance projects focused on sustainability, operational efficiency, and the modernization of our site, reinforcing our commitment to responsible manufacturing and environmental stewardship."

"Through the Life Sciences Scale-Up Fund, our government is ensuring that Ontario businesses are positioned to develop, commercialize and deploy new technologies across the health-care system," said Dawn Gallagher Murphy, Member of Provincial Parliament for Newmarket—Aurora. "With this investment, Piramal will be positioned to turn their latest ideas into market-ready solutions, all while creating good-paying jobs and reinforcing Ontario's position as a global biomanufacturing and life sciences hub."

First launched in 2024, the $24 million LSSUF works in tandem with the government's Health Innovation Pathway to advance the objectives of Phase 2 of Ontario's Life Sciences Strategy and strengthen Ontario's position as a global leader in health innovation. Building on the fund's initial success, the 2026 Ontario Budget invested an additional $24 million to support Ontario companies whose work will accelerate the adoption of innovative technologies in the health-care system and support the province's broader vision of providing connected, convenient care closer to home.

"Ontario's life sciences sector plays a critical role in supporting the discovery and development of innovative medicines and technologies, which is why our government is proud to support local companies as they take their Ontario-made products to the next level," said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. "By investing in Piramal through the Life Sciences Scale-Up Fund, we are scaling up our province's domestic capacity while further positioning Ontario as a leading jurisdiction for life sciences investment for generations to come."

By investing in the Aurora site, the Ontario government is strengthening Ontario's leadership in the life sciences and helping PPS advance next-generation technologies to patients worldwide.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.

For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X

About Piramal Pharma Limited
 

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.

For more information, visit: Piramal Pharma | LinkedIn

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility

Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility

Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility

Persistent Contextual Memory lets purpose-built Skills share the same understanding of content across multiple deliverables.

BURBANK, Calif., Sept. 30, 2026 /PRNewswire/ -- Iyuno today detailed the first set of 10 CLOE Skills, built around the needs of modern localization and the high-quality outputs required. These first 10 Skills include subtitles and SDH, closed captioning, dubbing and audio description scripts, localization, dialogue and spotting lists, show guides, and sensitive events lists, with additional Skills continuously being developed.

CLOE Skills leverage the persistent understanding of the content through the contextual memory rather than requiring AI to interpret the content from scratch each time.

Most AI workflows still treat each task as a new problem. Content goes in, the system interprets it, produces an output, and the process starts again.

CLOE is built around a different idea: understanding should persist.

Once CLOE builds a Contextual Memory for a title, its understanding of characters, relationships, dialogue, terminology, story events, and creative context can be applied across multiple specialized Skills.

"Subtitling, dubbing, audio description and production scripting require different expertise," David Lee, Iyuno Founder and CEO, said. "They shouldn't be treated as one generic AI problem. What they should share is an accurate understanding of the story. Skills let us specialize the execution without rebuilding the intelligence underneath it."

As CLOE continues to evolve, Iyuno plans to expand its Skills ecosystem across additional creative, operational, and audience-facing applications—enabling content organizations to activate understanding in new ways throughout the content lifecycle.

Build the understanding once. Put it to work everywhere.

For more information about CLOE, visit iyuno.com/cloe.

ABOUT IYUNO

Iyuno (www.iyuno.com) is a leading provider of localization services for the media and entertainment industry. Trusted by top entertainment brands and creators worldwide, Iyuno offers comprehensive end-to-end localization services from 40 offices across 29 countries. Backed by a team of exceptional creative and technical talent, state-of-the-art facilities, and cutting-edge technologies, Iyuno proudly boasts the largest global footprint, amplifying its dubbing, subtitling, and media services offerings. The company is also the creator of CLOE, a contextual intelligence platform that transforms content into structured understanding, enabling AI-powered workflows across localization, accessibility, marketing, and emerging content experiences.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

One Understanding, Many Outputs: Iyuno Announces the CLOE Skills Powering Modern Localization